Improving diagnosis of ovarian cancer using imaging methods

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the diagnosis of adnexal masses by implementing systematic image descriptions and evaluating various imaging methods and biomarkers. It focuses on distinguishing between benign and malignant adnexal masses through ultrasonography, MRI, and PET-CT, guided by IOTA recommendations. The study will also assess the management of conservatively treated adnexal masses by monitoring complications and longitudinal changes. Data will be collected prospectively but analyzed retrospectively, ensuring adherence to national and regional clinical guidelines.

Why it matters

Who can join: the full rules

Patients with an adnexal mass observed at ultrasonography.

Where it's running

• Department of Gynaecology and Obstetrics, Aarhus University Hospital
  Aarhus, Denmark Recruiting

Study contacts

• Principal investigator: Ina Marie Dueholm Hjorth, MD — University of Aarhus
• Study coordinator: Ina Marie Dueholm Hjorth, MD
• Email: imhjorth@gmail.com
• Phone: +004526192456

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing open and robotic surgery for women with complex pelvic masses

  This study is testing whether open surgery or robotic surgery is better for women with suspicious pelvic masses that are 8 cm or smaller.

  Recruiting Royal Surrey County Hospital NHS Foundation Trust · Guildford · NCT06638593

• Raludotatug Deruxtecan With or Without Bevacizumab as First‑Line Maintenance in Advanced Ovarian Cancer

  This trial tests whether maintenance therapy with raludotatug deruxtecan, with or without bevacizumab, helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer live longer without the cancer growing after initial treatment.

  Recruiting at 13 sites Phase 3 Merck Sharp & Dohme LLC · Washington D.C., District of Columbia and 12 other locations · NCT07776691

• Sac-TMT maintenance for people with non-HRD advanced ovarian cancer

  This trial sees if sacituzumab tirumotecan (sac‑TMT), given with or without bevacizumab, can keep cancer from getting worse after surgery and first‑line platinum chemotherapy in people with non‑HRD advanced ovarian cancer.

  Recruiting at 177 sites Phase 3 Merck Sharp & Dohme LLC · Birmingham, Alabama and 176 other locations · NCT07318558

• Using ultrasound microvessel imaging to evaluate ovarian and adnexal lesions

  This test tries to see if ultrasound microvessel imaging can better detect small blood vessels in adults scheduled for surgery for ovarian or adnexal lesions.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07280312

• Overcoming immune suppression and rebalancing the immune response in ovarian cancer

  We will try to find and reverse immune suppression by analyzing bone marrow, blood, spleen, peritoneal fluid, and tumor samples from women having surgery for ovarian cancer.

  Recruiting Gynaecologisch Oncologisch Centrum Zuid · Eindhoven, North Brabant · NCT06611072

• Evaluating NKT3964 for Adults with Advanced Solid Tumors

  This study is testing a new drug called NKT3964 to see if it can safely help adults with advanced solid tumors, like ovarian or triple-negative breast cancer, after other treatments have failed.

  Recruiting at 17 sites Phase 1 NiKang Therapeutics, Inc. · Little Rock, Arkansas and 20 other locations · NCT06586957

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.